Skip to main content
Publications
Anthony L, Horsch D, Ervin C, Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews. Poster presented at the 8th Symposium of the North American Neuroendocrine Tumor Society; October 15, 2015. Austin, TX.
Rubio-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J, Spanish Group for Research on Sarcoma. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8
Masclee GMC, Valkoff VE, Straatman H, Herings R, Garbe E, Schink T, Kollhorst B, Arfe A, Lucchi S, Villa M, Castellsague J, Perez-Gutthann S, Varas-Lorenzo C, Schade R, Schuemie M, Vergouwe Y, Steyerberg E, Sturkenboom M, Romio S. Individualized NSAID prescribing based on gastrointestinal and cardiovascular risks: a decision model in the SOS project. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):36-7. doi: 10.1002/pds.3838
Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946